Adcentrx Therapeutics to Present First Clinical Data for ADRX-0706 Nectin-4 ADC at ASCO 2025
Data provide clinical proof of concept for Adcentrx's novel technology platform; highlight unique opportunity for ADRX-0706 to address significant unmet needs for patients with limited therapeutic options
SAN DIEGO, April 23, 2025 /PRNewswire/ — Adcentrx Therapeutics ('Adcentrx'), a clinical-stage biotechnology company redefining Antibody-Drug Conjugate (ADC) therapies for cancer treatment and other life-threatening diseases, will present the first clinical data for ADRX-0706 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (May 30 – June 3, 2025) in Chicago, IL.
Adcentrx will deliver a poster presentation on ADRX-0706, a clinical-stage Nectin-4 ADC. The presentation will include interim clinical data from the Phase 1a portion of the ongoing trial (NCT06036121), demonstrating the best-in-class potential for ADRX-0706. The findings indicate a differentiated safety and pharmacokinetic profile, including a significantly lower incidence of critically meaningful adverse events such as peripheral neuropathy. Additionally, preliminary efficacy signals across different dose levels and tumor types provide strong clinical validation of Adcentrx's ADC platform, including the i-Conjugation® technology and novel auristatin payload AP052.
The first-in-human Phase 1a/b study is an open-label, two-part trial being conducted at sites in the U.S. and China. The completed Phase 1a portion consisted of a dose escalation of ADRX-0706 to evaluate initial safety and tolerability in patients with select advanced solid tumors, and to identify the recommended dose to be used in Phase 1b. This ongoing second portion of the study aims to further evaluate ADRX-0706's safety and tolerability, preliminary efficacy, and optimal dose in urothelial, triple-negative breast and cervical cancers.
Details of the poster presentation at the ASCO Meeting are as follows:
Title: Preliminary results from a first-in-human phase 1 dose escalation trial of ADRX-0706, a next generation Nectin-4 ADC, in subjects with advanced solid tumorsAbstract Number: 3018Session Date & Time: Monday, June 2, 1:30 p.m. – 4:30 p.m. CSTSession Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
The full abstract will be published by ASCO in conjunction with the Meeting.
About i-Conjugation® TechnologyAdcentrx's proprietary i-Conjugation® technology platform is a core component in the design of the company's ADCs. The platform utilizes protease-cleavable linkers and stable conjugation chemistry to enhance payload delivery. This advanced technology ensures a highly stable ADC with the desired linker-payload.
About ADRX-0706ADRX-0706 is a fully proprietary ADC product candidate discovered by Adcentrx. The antibody component is a novel fully human IgG1 targeting Nectin-4, a cell surface adhesion protein with high expression in multiple solid tumors and limited expression in normal tissues. Nectin-4 is associated with poor disease prognosis and is a validated target for ADCs.
The ADRX-0706 antibody is linked to a proprietary tubulin inhibitor payload, AP052, through Adcentrx's innovative i-Conjugation® technology using a cleavable linker and stable conjugation chemistry. This novel platform technology enables a highly stable ADC with a drug-antibody ratio of eight (DAR 8) with a substantially expanded therapeutic window as demonstrated in preclinical studies.
ADRX-0706 has a favorable pharmacokinetic and safety profile in preclinical models and has demonstrated significant efficacy across a variety of tumor indications in vitro and in vivo. ADRX-0706 is currently being evaluated in a Phase 1a/b clinical trial.
For more information about the ADRX-0706 Phase 1a/b clinical trial, please refer to the Study ID NCT06036121 on ClinicalTrials.gov.
About Adcentrx TherapeuticsAdcentrx is a biotechnology company focused on accelerating breakthroughs in protein conjugate therapeutic development for cancer and other life-threatening diseases. Adcentrx has pioneered the development of an ADC technology platform addressing key components of protein conjugate design to solve challenges typically seen in ADCs. Adcentrx is developing a robust pipeline including two clinical-stage ADCs and multiple preclinical ADCs, all with first-in-class and best-in-class potential.
For more information about Adcentrx and its innovative ADC technologies, please visit https://adcentrx.com.
Contact Information:Investor Relationsir@adcentrx.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
2 hours ago
- Malaysian Reserve
Respiratory Care Devices Market worth $33.6 billion by 2030 with 7.3% CAGR
DELRAY BEACH, Fla., July 14, 2025 /PRNewswire/ — The global Respiratory Care Devices Market, valued at US$22.2 billion in 2024 stood at US$23.6 billion in 2025 and is projected to advance at a resilient CAGR of 7.3% from 2025 to 2030, culminating in a forecasted valuation of US$33.6 billion by the end of the period. The advanced wound care market is primarily driven by several factors: the increasing geriatric population, the rising prevalence of chronic diseases, and a growing number of traumatic and burn injuries. These elements have significantly boosted the demand for effective wound management solutions. Furthermore, supportive government initiatives and reimbursement frameworks contribute to market growth. Download PDF Brochure: Browse in-depth TOC on 'Respiratory Care Devices Market' 587 – Tables63 – Figures466 – Pages By product type, Therapeutic devices are necessary for managing and treating the majority of acute and chronic respiratory diseases. They are required to provide patients with COPD, asthma, sleep apnea, and respiratory failure with life-sustaining respiratory therapy. The devices include high-flow nasal cannula systems, CPAP and BiPAP devices, nebulizers, ventilators, and oxygen concentrators. The therapeutic equipment market has increased manifold due to the need for long-term home-based respiratory therapy, the global burden of chronic disease, and the increase in hospitalization. By disease indication, the respiratory care devices market is dominated by Chronic Obstructive Pulmonary Disease (COPD), which is increasingly becoming a global phenomenon, especially in the elderly population. This is due to higher demand for non-invasive ventilators, oxygen concentrators, nebulizers, and monitors. Since COPD is progressive and irreversible, it requires constant care and long-term respiratory therapy. The disease is also escalated by high-risk factors prevalent in developing and developed countries, including smoking, air pollution, and occupational exposures. Furthermore, since COPD is hospitalized and receives exacerbations, constant use of respiratory equipment at home and in the hospital is required. By geography, the respiratory care devices market is segmented into five major regions, namely, North America, Europe, Asia Pacific (APAC), Latin America, Middle East and Africa. The prevalence of chronic respiratory illnesses such as asthma, COPD, and sleep apnea is partly due to the aging population, extensive histories of smoking, and rising obesity. The strong healthcare infrastructure of the region and growing awareness of the significance of respiratory health enable early detection and treatment of such conditions. The COVID-19 pandemic also drove demand for oxygen therapy equipment and ventilators and hence created long-term interest and investment in respiratory care products. Large medical device firms, improved reimbursement policies, and quick adoption of new technology such as remote monitoring and telephonic integration of respiratory equipment have also driven the market. Request Sample Pages : The key players in the global respiratory care devices market are Koninklijke Philips N.V. (Netherlands), Medtronic (Ireland), ResMed Inc. (US), Fisher & Paykel Healthcare Limited (New Zealand), Drägerwerk AG & Co. KGaA (Germany), GE Healthcare (US), Masimo (US), Getinge (Sweden), Nihon Kohden Corporation (Japan), Hillrom & Welch Allyn (Baxter) (US), Teleflex Incorporated (Japan), Air Liquide (France), ICU Medical, Inc (US), AdaptHealth, LLC (US), Hamilton Medical (Switzerland), Medline Industries, LP (US), Allied Medical, LLC (US), Nonin (US), Apex Medical (Taiwan), Rotech Healthcare Inc. (US), Löwenstein Medical SE & Co. KG (Germany), WEINMANN Emergency Medical Technology GmbH + Co. KG (Germany), Drive DeVilbiss Healthcare (US), OMRON Healthcare, Inc (Japan) and HUM GmbH (Germany). Koninklijke Philips N.V. (Netherlands): Koninklijke Philips N.V. is a global health technology leader known for its strong presence in the respiratory care devices market, particularly through its innovative, non-invasive ventilators, CPAP/BiPAP machines, and home oxygen therapy systems. With a strategic focus on integrated care, Philips combines medical devices with AI-powered digital platforms such as HealthSuite to deliver connected solutions across hospital and home settings. The company's core competencies lie in its robust R&D capabilities, global brand presence, and commitment to sustainability. Despite challenges from a global recall of certain respiratory devices, Philips continues to strengthen its position through new product launches. These efforts underline its leadership in delivering advanced, patient-centric respiratory care solutions globally. Medtronic (Ireland) Medtronic plc is one of the world's largest medical technology companies, operating in over 150+ countries. The company has merged its remaining Patient Monitoring and Respiratory Interventions segments into a unified business unit named Acute Care & Monitoring. Its core competencies include its strong presence in chronic disease management, cutting-edge patient monitoring systems, surgical innovations, and global supply chain capabilities. Known for its continuous investment in R&D and digital health integration, the company excels in developing minimally invasive therapies, advanced monitoring devices, and AI-powered diagnostics. Despite withdrawing from ventilator manufacturing, the company remains a major player in hospital-based care solutions, focusing on innovation in acute monitoring and intervention technologies. This restructuring reflects the aim to streamline operations, enhance profitability, and concentrate on higher-growth segments in critical and surgical care. For more information, Inquire Now! Related Reports: Respiratory Diagnostics Market Molecular Diagnostics Market In Vitro Diagnostics Market Point of Care Molecular Diagnostics Market Infectious Disease Diagnostics Market Get access to the latest updates on Respiratory Care Devices Companies and Respiratory Care Devices Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter , LinkedIn and Facebook . Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content:
Malaysian Reserve
4 hours ago
- Malaysian Reserve
Florida Cancer Specialists & Research Institute Strengthens Local Access to Cancer Care with Physician Appointments in Major Markets
Statewide Practice Welcomes Medical Oncologist & Hematologist Marisabel H. Castillo, MD to Palm Beach County; Medical Oncologist & Hematologist Roderick Paras, MD to Central Florida FORT MYERS, Fla., July 14, 2025 /PRNewswire/ — Florida Cancer Specialists & Research Institute, LLC (FCS) welcomes medical oncologists and hematologists Marisabel H. Castillo, MD and Roderick Paras, MD to the statewide practice. Dr. Castillo is providing care to patients at the FCS Boca Raton clinic, 21020 State Road 7, Ste. 200C, Boca Raton, FL 33428, and the FCS Delray Beach clinic, 5130 Linton Blvd., Ste. B4, Delray Beach, FL 33484. She graduated magna cum laude from the Central University of Venezuela in Caracas. She received the Outstanding Continuity Clinic Resident Award during her internal medicine residency at New York University and was later appointed chief fellow during her hematology/medical oncology fellowship at the University of Texas at Austin. 'Dr. Castillo is an accomplished physician recognized early in her career for several distinguished achievements, said FCS Assistant Managing Physician David Wenk, MD. 'Through active involvement in clinical research, Dr. Castillo has contributed to the development of innovative immunotherapies as well as strategies to identify and reduce disparities in cancer diagnosis and treatment. She will utilize her skills and dedication to ensure our patients in Palm Beach County attain the best outcomes.' Dr. Paras is providing care to patients at the FCS cancer centers in Lake Mary, 805 Currency Cir., Lake Mary, FL 32746, Deland, 810 N. Spring Garden Ave., Ste 100, Deland, FL 32720 and Orange City, 2824 Enterprise Rd., Orange City, FL 32763. After completing his medical degree at the University of Santo Tomas in Manila, Dr. Paras completed internal medicine residency training at New York Medical College's St. Vincent's Medical Center and a fellowship in medical oncology at Medical College of Pennsylvania in Pittsburgh. FCS President & Managing Physician Lucio N. Gordan, MD, said, 'With a wealth of experience in oncology and a deep commitment to patient-centered care, Dr. Paras brings expertise as well as compassion that will strengthen our mission and elevate the care we provide in Seminole and Volusia counties.' Dr. Castillo and Dr. Paras are among the growing number of physicians choosing to grow their careers with FCS. About Florida Cancer Specialists & Research Institute, LLC: ( For more than 40 years, Florida Cancer Specialists & Research Institute (FCS) has embraced innovation to deliver world-class care and drive the dramatic transformation of oncology care through its robust clinical research program. FCS provides patients with access to a wide range of clinical trials, positioning it as a leader in research among private oncology practices in Florida and across the country. In fact, before receiving FDA approval, the majority of new cancer drugs in the U.S. were first made available to patients through participation in clinical trials at FCS. Our outstanding team of highly trained and dedicated physicians is committed to delivering tailored treatment plans that make the best use of cutting-edge precision oncology advancements to enhance patient outcomes.
Malaysian Reserve
4 hours ago
- Malaysian Reserve
CypressTel Unveils New Logo and Brand Identity to Mark 17 Years of Growth and Innovation
HONG KONG, July 14, 2025 /PRNewswire/ — Cypress Telecom Limited ('CypressTel') proudly marks its 17th anniversary with a significant brand refresh, introducing a new logo and adopting a bold new positioning as the 'Global Innovator in AIGC Network and Security Managed Services'. Alongside this, the company launches a new slogan: 'Secure . Connect . Innovate'. This milestone reflects CypressTel's strategic evolution from a traditional network provider to a leader in AI-driven intelligent network and security solutions, setting a new direction for the telecommunications industry across the Asia-Pacific region and beyond. The redesigned logo features three fluid ellipses in vibrant blue, symbolizing growth, resilience, and continuous innovation in secure connectivity. Inspired by unfolding leaves, the design represents CypressTel's ability to adapt and thrive in a rapidly evolving industry. The interlocking shapes highlight the company's deep expertise in network technology and its commitment to delivering intelligent, secure connectivity. The ellipses also form an abstract 'C,' reinforcing CypressTel's distinctive brand identity. This evolution mirrors the company's journey—from a traditional, layered design symbolizing foundational network building to a dynamic, borderless form that embodies intelligent, secure, and global connectivity. CypressTel's refreshed brand positioning highlights its dedication to integrating advanced AI technologies into network and security services. With proprietary AI security engines capable of analyzing encrypted traffic and processing over 100,000 daily threat intelligence data points, CypressTel offers real-time, dynamic defense against emerging cyber threats. Its intelligent SD-WAN and SASE platform, along with edge security solutions, empowers enterprises across various industries to enhance network efficiency and security amid an increasingly complex digital landscape. As the 'Global Innovator in AIGC Network and Security Managed Services,' CypressTel empowers enterprises to detect and respond to threats in real time using AI-driven security engines, optimize network performance for large-scale cloud data flows, and support digital transformation and global expansion through seamless, secure connectivity. Since its establishment in 2008, CypressTel has expanded into a trusted global partner with a presence in over 300 cities and more than 140 Points of Presence worldwide. This brand upgrade not only celebrates nearly two decades of expertise but also signals CypressTel's readiness to lead the future of telecommunications, where network security and AI-driven innovation are crucial. Connee, CEO of CypressTel, stated: 'Our new logo and brand identity signify more than a visual change—they embody our commitment to lead the industry into the AI era. As connectivity becomes universal, only those who integrate intelligent networks, security, and AI innovation at their core will thrive. Each time our logo appears, it expresses our belief in technology and our vision for limitless, AI-powered connectivity. This symbol represents CypressTel's mission to drive the next golden age of AI-Powered Networking.' For further information, interviews, or media requests, please contact:Cypress Telecom LimitedName: Abbie LeeTitle: Marketing ManagerEmail: contact@ +852 3704 9334Website:
